Sunday, December 8, 2019
Recently, Exelixis declared that the U.S. FDA (Food and Drug Administration) has granted approval for Cabometyx (cabozantinib) tablets for individuals having HCC (hepatocellular carcinoma) and who have been earlier treated with sorafenib. HCC is the main general form of liver cancer and the fastest-mounting cause of cancer-interrelated fatalities in...